5-azacytidine
BRCA1 Gene Mutation
Ohio State University Comprehensive Cancer CenterPhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
10 Active assets in the BRCA1 Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Olaparib M.D. Anderson Cancer Center | Phase 2 | BB |
Niraparib Qian Qin | Phase 3 | B |
Rucaparib University of Washington | Phase 2 | B |
Veliparib Steven J Isakoff, MD, PhD | Phase 2 | B |
Durvalumab Roswell Park Cancer Institute | Phase 2 | B |
View all 17 →
Same molecule, other indications
5-azacytidine is also rated in:
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic LeukemiaDormant
BB
Indicative ·
65 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →